Masofaniten

DB21580InvestigationalSmall molecule

Masofaniten is a small molecule drug. Masofaniten is under investigation in clinical trial NCT06312670 (Combining EPI-7386 With Enzalutamide and Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer). Masofaniten has a... Masofaniten has a monoisotopic molecular weight of 534.09 Da.

Mechanism: Pharmacologically active on Androgen receptor
Curator reviewed
Formula / weight: C₂₄H₂₄Cl₂N₄O₄S · 535.44 g/mol (avg)
Code names: EPI-7386

Resolves to

Compound

UNIIOQ2SF7P8B2CAS2416716-62-4ChEMBLCHEMBL5095106ChEBI758689PubChem146484310

Structure

InChIKeyGVCZSODXLFBYSS-UHFFFAOYSA-NSMILESCC(C)(C1=CC=C(OCC2=NC(NS(C)(=O)=O)=NC=C2)C=C1)C1=CC(C#N)=C(OCCCl)C(Cl)=C1

Targets

P10275AR

What you can answer from here — as of September 23, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

1+ReferenceStructured and connected to the statements they support

Which drugs share a target with Masofaniten, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account